Valneva: EMA Leans on IXCHIQ After Serious Cases
Valneva‘s Chikungunya Vaccine Faces EMA Review Over Adverse Effects
Table of Contents
- Valneva’s Chikungunya Vaccine Faces EMA Review Over Adverse Effects
- Valneva’s Chikungunya Vaccine: Answering Your Questions
- what is the IXCHIQ vaccine?
- What is the Chikungunya virus?
- Why is the European Medicines Agency (EMA) reviewing the IXCHIQ vaccine?
- What kind of adverse effects are being reported?
- Who is most affected by the adverse effects?
- How many doses of the vaccine have been administered?
- How many cases of serious adverse effects have been reported?
- What specific actions are being taken regarding the vaccine?
- Is the vaccine still available for everyone?
- What is the EMA’s stance on the link between the vaccine and adverse events?
- What are the known contraindications for the IXCHIQ vaccine?
- What is Valneva’s response to the review?
- Summary: Key facts About the IXCHIQ Vaccine
PARIS (Circlefinance.com) — Teh European Medicines Agency (EMA) has initiated a review of Valneva’s IXCHIQ vaccine, designed to protect against the chikungunya virus, following reports of serious adverse effects, particularly among elderly recipients, Valneva announced.
Limited Use, Adverse Reactions Trigger Review
To date, over 40,000 doses of the IXCHIQ vaccine have been administered globally. Though, 17 cases of serious adverse effects have been reported, including two incidents involving individuals over the age of 65.
Vaccine Use Suspended for Those Over 65
As a precautionary measure, the use of the vaccine has been temporarily suspended for individuals aged 65 and older. The vaccine remains available for those between 12 and 64 years of age.
EMA Cites ‘Uncertain’ Link,Highlights Contraindications
The EMA emphasizes that the connection between the reported adverse events and the IXCHIQ vaccination remains “uncertain.” The agency also reiterated existing contraindications for the vaccine, specifically in cases of immunosuppression.
Valneva Reaffirms Commitment to Safety
While adjustments have been implemented in the United States and France, Valneva has reaffirmed its commitment to vaccine safety. The company maintains that the benefit-risk ratio of the IXCHIQ vaccine remains favorable.
Valneva’s Chikungunya Vaccine: Answering Your Questions
This article provides details about Valneva’s IXCHIQ chikungunya vaccine, based on the information provided in the source material.
what is the IXCHIQ vaccine?
The IXCHIQ vaccine, manufactured by Valneva, is designed too protect individuals against the chikungunya virus.
What is the Chikungunya virus?
The source material doesn’t provide details on the Chikungunya virus,however here is some additional information you might find useful. The chikungunya virus is transmitted to humans through the bites of infected mosquitoes, primarily Aedes aegypti and aedes albopictus. Symptoms often include fever and severe joint pain.
Why is the European Medicines Agency (EMA) reviewing the IXCHIQ vaccine?
The EMA is reviewing the IXCHIQ vaccine due to reports of serious adverse effects following its administration. This review was initiated after Valneva announced the reports.
What kind of adverse effects are being reported?
The article specifies “serious adverse effects” are the primary concern. The full nature of these effects isn’t specified in the provided document.
Who is most affected by the adverse effects?
The reports of serious adverse effects are particularly concentrated among elderly recipients (those over 65).
How many doses of the vaccine have been administered?
Over 40,000 doses of the IXCHIQ vaccine have been administered globally, according to the source material.
How many cases of serious adverse effects have been reported?
There have been 17 reported cases of serious adverse effects.
What specific actions are being taken regarding the vaccine?
As a precautionary measure, the use of the IXCHIQ vaccine has been temporarily suspended for individuals aged 65 and older.
Is the vaccine still available for everyone?
No. While the vaccine is suspended for those 65 and over, it remains available for individuals between the ages of 12 and 64.
What is the EMA’s stance on the link between the vaccine and adverse events?
The EMA states that the connection between the reported adverse events and the IXCHIQ vaccination remains “uncertain.”
What are the known contraindications for the IXCHIQ vaccine?
The EMA reiterated existing contraindications,particularly for those with immunosuppression. That is, if you have a weakened immune system, IXCHIQ may not be appropriate for you.
What is Valneva’s response to the review?
Valneva has reaffirmed its commitment to vaccine safety. They also maintain that the benefit-risk ratio of the IXCHIQ vaccine remains favorable. They have also implemented adjustments in the United States and France.
Summary: Key facts About the IXCHIQ Vaccine
| Aspect | Details |
| ————————– | ————————————————————————– |
| Vaccine Name | IXCHIQ |
| Manufacturer | Valneva |
| Target Illness | Chikungunya virus |
| Review trigger | Reports of serious adverse effects |
| Specific Concern | Adverse effects in elderly recipients (over 65) |
| Doses Administered | Over 40,000 globally |
| Reported Adverse Events | 17 cases |
| Age Restrictions | suspended for ages 65+,available ages 12-64. |
| EMA Stance | Connection to adverse events “uncertain” |
| Contraindications | Immunosuppression |
| Valneva’s Position | Reaffirms commitment to safety; benefit-risk ratio remains favorable. |